LSTA

#4144
Lisata Therapeutics, Inc. - Common Stock
3.2 5 USD
-1.81%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.25
3.25
Jahresspanne
1.81
5.06
Tagesänderung
-1.81%
Monatliche Änderung
+1.25%
6 month change
+58.54%
Jahresänderung
+16.49%
Vorheriger Schlusskurs
3.3 1
Open
3.2 5
Tief
3.2 5
High
3.2 5
Volumen
4
Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
Gewinn- und Verlustrechnung Bilanz Cashflow
Wert 20202021202220232024 TTM

Lisata Therapeutics, Inc. - Common Stock

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

Nachrichten